WO2001089550A2 - Use of ciliary neurotrophic factor - Google Patents
Use of ciliary neurotrophic factor Download PDFInfo
- Publication number
- WO2001089550A2 WO2001089550A2 PCT/US2001/040783 US0140783W WO0189550A2 WO 2001089550 A2 WO2001089550 A2 WO 2001089550A2 US 0140783 W US0140783 W US 0140783W WO 0189550 A2 WO0189550 A2 WO 0189550A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cntf
- neurotrophic factor
- ciliary neurotrophic
- human
- protein
- Prior art date
Links
- 108010005939 Ciliary Neurotrophic Factor Proteins 0.000 title claims abstract description 118
- 102100031614 Ciliary neurotrophic factor Human genes 0.000 title claims abstract description 117
- 238000000034 method Methods 0.000 claims abstract description 37
- 208000008589 Obesity Diseases 0.000 claims abstract description 31
- 235000020824 obesity Nutrition 0.000 claims abstract description 30
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 13
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims abstract description 9
- 208000004104 gestational diabetes Diseases 0.000 claims abstract description 8
- 230000000241 respiratory effect Effects 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 31
- 241000282414 Homo sapiens Species 0.000 claims description 29
- 230000004580 weight loss Effects 0.000 claims description 19
- 235000005911 diet Nutrition 0.000 claims description 18
- 230000037213 diet Effects 0.000 claims description 17
- 241000124008 Mammalia Species 0.000 claims description 9
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 239000006199 nebulizer Substances 0.000 claims description 5
- 230000001939 inductive effect Effects 0.000 claims description 4
- 210000002161 motor neuron Anatomy 0.000 claims description 4
- 210000000278 spinal cord Anatomy 0.000 claims description 4
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 3
- 210000002932 cholinergic neuron Anatomy 0.000 claims description 3
- 210000004295 hippocampal neuron Anatomy 0.000 claims description 3
- 210000004081 cilia Anatomy 0.000 claims 1
- 230000003412 degenerative effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 description 66
- 241000699670 Mus sp. Species 0.000 description 53
- 102000004169 proteins and genes Human genes 0.000 description 52
- 235000018102 proteins Nutrition 0.000 description 51
- 101000993364 Homo sapiens Ciliary neurotrophic factor Proteins 0.000 description 38
- 101000993333 Rattus norvegicus Ciliary neurotrophic factor Proteins 0.000 description 26
- 102000016267 Leptin Human genes 0.000 description 24
- 108010092277 Leptin Proteins 0.000 description 24
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 24
- 229940039781 leptin Drugs 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 20
- 208000016261 weight loss Diseases 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- 230000037396 body weight Effects 0.000 description 18
- 239000003981 vehicle Substances 0.000 description 18
- 238000006467 substitution reaction Methods 0.000 description 15
- 230000027455 binding Effects 0.000 description 14
- 208000035475 disorder Diseases 0.000 description 14
- 235000012631 food intake Nutrition 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 230000004071 biological effect Effects 0.000 description 13
- 239000000872 buffer Substances 0.000 description 13
- 230000037406 food intake Effects 0.000 description 13
- 230000037230 mobility Effects 0.000 description 13
- 201000010099 disease Diseases 0.000 description 12
- 210000002569 neuron Anatomy 0.000 description 12
- 235000001014 amino acid Nutrition 0.000 description 11
- 230000001886 ciliary effect Effects 0.000 description 11
- 239000013612 plasmid Substances 0.000 description 11
- 108020003175 receptors Proteins 0.000 description 11
- 102220141930 rs778259023 Human genes 0.000 description 11
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 10
- 102000005962 receptors Human genes 0.000 description 10
- 102200015136 rs398122975 Human genes 0.000 description 10
- 230000004083 survival effect Effects 0.000 description 10
- 102000016989 Ciliary Neurotrophic Factor Receptor Human genes 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 238000000746 purification Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000010254 subcutaneous injection Methods 0.000 description 8
- 239000007929 subcutaneous injection Substances 0.000 description 8
- 102100031615 Ciliary neurotrophic factor receptor subunit alpha Human genes 0.000 description 7
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 101000993348 Homo sapiens Ciliary neurotrophic factor receptor subunit alpha Proteins 0.000 description 7
- 239000007983 Tris buffer Substances 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 7
- 108010000063 Ciliary Neurotrophic Factor Receptor Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 208000003098 Ganglion Cysts Diseases 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 6
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 6
- 208000005400 Synovial Cyst Diseases 0.000 description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 210000003000 inclusion body Anatomy 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 229920002684 Sepharose Polymers 0.000 description 5
- 210000000577 adipose tissue Anatomy 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 5
- 235000011130 ammonium sulphate Nutrition 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 231100000673 dose–response relationship Toxicity 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000012510 hollow fiber Substances 0.000 description 5
- 230000003389 potentiating effect Effects 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000007921 spray Substances 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- OMFXVFTZEKFJBZ-UHFFFAOYSA-N Corticosterone Natural products O=C1CCC2(C)C3C(O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 OMFXVFTZEKFJBZ-UHFFFAOYSA-N 0.000 description 4
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 125000000539 amino acid group Chemical group 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 230000001174 ascending effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- OMFXVFTZEKFJBZ-HJTSIMOOSA-N corticosterone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OMFXVFTZEKFJBZ-HJTSIMOOSA-N 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 235000009200 high fat diet Nutrition 0.000 description 4
- 229930027917 kanamycin Natural products 0.000 description 4
- 229960000318 kanamycin Drugs 0.000 description 4
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 4
- 229930182823 kanamycin A Natural products 0.000 description 4
- 238000002703 mutagenesis Methods 0.000 description 4
- 231100000350 mutagenesis Toxicity 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000004166 bioassay Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000004191 hydrophobic interaction chromatography Methods 0.000 description 3
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 3
- 201000008980 hyperinsulinism Diseases 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 230000006320 pegylation Effects 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 239000013615 primer Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 108091008146 restriction endonucleases Proteins 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000001488 sodium phosphate Substances 0.000 description 3
- 229910000162 sodium phosphate Inorganic materials 0.000 description 3
- 239000012064 sodium phosphate buffer Substances 0.000 description 3
- 210000002222 superior cervical ganglion Anatomy 0.000 description 3
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000011725 BALB/c mouse Methods 0.000 description 2
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101100384385 Homo sapiens CNTF gene Proteins 0.000 description 2
- 108090000144 Human Proteins Proteins 0.000 description 2
- 102000003839 Human Proteins Human genes 0.000 description 2
- 102000010781 Interleukin-6 Receptors Human genes 0.000 description 2
- 108010038501 Interleukin-6 Receptors Proteins 0.000 description 2
- 102100031775 Leptin receptor Human genes 0.000 description 2
- 102100021747 Leukemia inhibitory factor receptor Human genes 0.000 description 2
- 101710142062 Leukemia inhibitory factor receptor Proteins 0.000 description 2
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 2
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 208000017442 Retinal disease Diseases 0.000 description 2
- 239000012506 Sephacryl® Substances 0.000 description 2
- 102000000887 Transcription factor STAT Human genes 0.000 description 2
- 108050007918 Transcription factor STAT Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000007998 bicine buffer Substances 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 238000013229 diet-induced obese mouse Methods 0.000 description 2
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 235000019138 food restriction Nutrition 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 229920001427 mPEG Polymers 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000003900 neurotrophic factor Substances 0.000 description 2
- 210000001328 optic nerve Anatomy 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 230000003234 polygenic effect Effects 0.000 description 2
- 150000003141 primary amines Chemical class 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 231100000272 reduced body weight Toxicity 0.000 description 2
- 235000018770 reduced food intake Nutrition 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000008093 supporting effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 239000013585 weight reducing agent Substances 0.000 description 2
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- 101100002068 Bacillus subtilis (strain 168) araR gene Proteins 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 101150030072 CNTF gene Proteins 0.000 description 1
- 108010010079 Ciliary Neurotrophic Factor Receptor alpha Subunit Proteins 0.000 description 1
- 102000015771 Ciliary Neurotrophic Factor Receptor alpha Subunit Human genes 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 229920002271 DEAE-Sepharose Polymers 0.000 description 1
- 108020001019 DNA Primers Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000001712 DNA sequencing Methods 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- 102000015617 Janus Kinases Human genes 0.000 description 1
- 108010024121 Janus Kinases Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710090149 Lactose operon repressor Proteins 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241001415846 Procellariidae Species 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 101100384389 Rattus norvegicus Cntf gene Proteins 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 108010017324 STAT3 Transcription Factor Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100024040 Signal transducer and activator of transcription 3 Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 101150044616 araC gene Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- -1 atomizer Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 108010014210 axokine Proteins 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 230000006583 body weight regulation Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000000256 facial nerve Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000009246 food effect Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000006481 glucose medium Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005734 heterodimerization reaction Methods 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 230000000910 hyperinsulinemic effect Effects 0.000 description 1
- 230000001127 hyperphagic effect Effects 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010019813 leptin receptors Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000014511 neuron projection development Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000002589 oculomotor nerve Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 108010055896 polyornithine Proteins 0.000 description 1
- 229920002714 polyornithine Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000029556 regulation of feeding behavior Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000001044 sensory neuron Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000004513 sizing Methods 0.000 description 1
- 238000010512 small scale reaction Methods 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 210000003594 spinal ganglia Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000008337 systemic blood flow Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention relates to ciliary neurotrophic factor (CNTF) and CNTF- related polypeptides useful for the treatment of neurological diseases, obesity and other diseases or disorders.
- CNTF ciliary neurotrophic factor
- CNTF is a protein that is required for the survival of embryonic chick ciliary ganglion neurons in vitro (Manthorpe et al., 1980, J. Neurochem. 34:69-75).
- the ciliary ganglion is anatomically located within the orbital cavity, lying between the lateral rectus and the sheath of the optic nerve; it receives parasympathetic nerve fibers from the oculomotor nerve which innervates the ciliary muscle and sphincter pupillae.
- CNTF is believed to induce the differentiation of bipotentia glial progenitor cells in the peri ⁇ atal rat optic nerve and brain (Hughes et al., 1988, Nature 335:70-73). Furthermore, it has been observed to promote the survival of embryonic chick dorsal root ganglion sensory neurons (Skaper and Varon, 1986, Brain Res. 389:39 46).
- CNTF supports the survival and differentiation of motor neurons, hippocampal neurons and presympathetic spinal cord neurons (Sendtner, et al., 1990, Nature 345: 440-441; Ip, et al. 1991, J. Neurosci. 11:3124-3134; Blottner, et al. 1989, Neurosci. Lett. 105:316 320).
- CNTF has been cloned and synthesized in bacterial expression systems, as described by Masiakowski, et al., 1991, J. Neurosci. 57:1003-1012 and in International Publication No. WO 91/04316, published on April 4, 1991, both of which are incorporated by reference in their entirety herein.
- recombinant human and rat CNTF differ in several respects.
- the biological activity of recombinant rat CNTF in supporting survival and neurite outgrowth from embryonic chick ciliary neurons in culture is four times better than that of recombinant human CNTF (rHCNTF) (Masiakowski et al., 1991, J. Neurochem. 57:1003-1012).
- rat CNTF has a higher affinity for the human CNTF receptor than does human CNTF (Davis et al,
- the CNTF receptor complex contains three proteins: a specificity determining ⁇ component that directly binds to CNTF, as well as two signal transducing ⁇ components (LIFR ⁇ and gpl30) that cannot bind CNTF on their own, but are required to initiate signaling in response to CNTF.
- the ⁇ component of the CNTFR complex is more widely distributed throughout the body than the ⁇ component.
- the 3 components of the CNTFR complex are normally unassociated on the cell surface; CNTF induces the stepwise assembly of a complete receptor complex by first binding to CNTFR , then engaging gpl30, and finally recruiting LIFR ⁇ .
- intracellular signaling is initiated by activating non-receptor tyrosine kinases QAK kinases) associated with the ⁇ components.
- QAK kinases respond by phosphorylating each other and also tyrosine residues on the receptor cytoplasmic domains, creating phosphotyrosine docking sites for the Src homology 2 domains of STAT proteins. After their phosphorylation, bound STAT proteins dissociate from the receptor, dimerize, and translocate to the nucleus where they bind DNA and activate transcription (reviews: Frank, D. and Greenberg, M. (1996) Perspectives on Developmental Neurobiology 4: 3-18; Stahl, N.
- Axokine is a mutant CNTF molecule with improved physical and chemical properties, which retains the ability to interact with and activate the CNTF receptor.
- Leptin the product of the ob gene, is secreted by adipocy tes and functions as a peripheral signal to the brain to regulate food intake and energy metabolism (Zhang, Y., et al. (1994) Nature 372: 425-431).
- leptin receptor a single membrane-spanning receptor
- gpl30 Tartaglia, L., et al. (1995) Cell 83: 1263-1271.
- Both CNTF and leptin each signals through the JAK/STAT pathway (Baumann, H., et al. (1996) Proc. Natl. Acad. Sci. USA 93: 8374-8378; Ghilardi, N., et al. (1996) Proc. Natl. Acad. Sci. USA 93: 6231- 6235).
- Systemic administration of both CNTF and leptin results in induction of tis-11 (Gloaguen, I., et al.
- An object of the present invention is to provide CNTF and CNTF-related proteins, collectively referred to herein as CNTF proteins, for the treatment of diseases or disorders including, but not limited to, obesity and diabetes.
- a further object of the present invention is to provide a method for administering CNTF or CNTF-related proteins and maintaining biological activity.
- a preferred embodiment of this invention is the administration of CNTF or a CNTF related protein to the nasal or respiratory system of a mammal to produce an increase in the level of the protein in the systemic blood circulation of the mammal.
- a particularly preferred embodiment comprises the administration of the modified CNTF molecule, designated herein as AX-15, to the nasal passages of a patient for the treatment of obesity or diabetes.
- FIG. 1 Alignment of CNTF protein sequences.
- A Human, rat, rabbit mouse and chicken (Leung, et al., 1992, Neuron 8:1045-1053) sequences. Dots indicate residues found in the human sequence.
- B Modified CNTF molecules showing human CNTF amino acid residues (dots) and rat CNTF (residues shown). The name of the purified recombinant protein corresponding to each sequence is shown on the left.
- Figure 2 Mobility of human, rat and several modified CNTF molecules on reducing SDS-15% polyacrylamide gels. Purified recombinant proteins were loaded as indicated. Markers of the indicated MW were loaded on lane M.
- FIG. 3 Effects of Axokine-15 (AX-15) in normal mice.
- AX-15 Axokine-15
- Normal C57BL/6J mice were injected subcutaneously daily for 6 days with either vehicle or AX-15 at 0.1 mg/kg, 0.3 mg/kg, or 1.0 mg/kg. Percent change in body weight in AX-15-treated versus vehicle-treated controls is shown.
- FIG. 4 Effects of AX-15 in ob/ob mice.
- C57BL/6J ob/ob mice were injected subcutaneously daily for 7 days with either vehicle, leptin (1.0 mg/kg) or AX-15 at 0.1 mg/kg, 0.3 mg/kg, 1.0 mg/kg or 3.0 mg/kg.
- Diet-restricted, pair-fed (PF) mice were injected with 0.3 mg/kg AX-15 to investigate the effects of food intake reduction on weight loss. Percent change in body weight in AX-15-treated and leptin-treated versus vehicle-treated controls is shown.
- FIG. 5 Effects of AX-15 in diet-induced obesity in mice.
- AKR/J mice were placed on a high fat diet for seven weeks prior to treatment with vehicle, leptin (1.0 mg/kg) or AX-15 at 0.03 mg/kg, 0.1 mg/kg, 0.3 mg/kg, or 1.0 mg/kg.
- Diet-restricted, pair- fed AKR/J mice were injected with 0.1 mg/kg AX-15 (PF-AX-15) to investigate the effects of food intake reduction on weight loss. Percent change in body weight in AX-15 -treated and leptin-treated versus vehicle-treated controls is shown.
- Figures 6A and 6B Effects of AX-15 and diet restriction on serum insulin and corticosterone levels in diet-induced obese AKR/J mice.
- Figure 6A- Serum insulin levels were measured in AKR/J diet-induced obese mice following treatment with vehicle, diet restriction and AX-15 (0.1 mg/kg) (PF-AX-15) or AX-15 only (0.1 mg/kg) to determine the effects of diet and/or AX-15 treatment on obesity- associated hyperinsulinemia.
- Figure 6B- Serum corticosterone levels were measured in AKR/J diet induced obese mice following treatment with vehicle, diet restriction and AX-15 (0.1 mg/kg) (PF-AX-15) or AX-15 only (0.1 mg/kg).
- FIG. 7 Effect of intranasal delivery of AX-15 on body weight reduction in diet- induced obese AKR/J mice.
- DIO mice were given daily intranasal administration of either vehicle (D) or AX-15 (94 ⁇ g/mouse in 50 ⁇ l, approximately 1.87-2.35 mg/kg) (0) for 7 days.
- a group of mice receiving daily subcutaneous injection of AX-15 (O) at 0.1 mg/kg was also included for comparison.
- FIG 8 Effect of intranasal delivery of AX-15 on food intake in diet-induced obese AKR/J mice.
- DIO mice were given daily intranasal administration of either vehicle (D) or AX-15 (94 ⁇ g/mouse in 50 ⁇ l, approximately 1.87-2.35 mg/kg) (0) for 7 days.
- a group of mice receiving daily subcutaneous injection of AX-15 (O) at 0.1 mg/kg was also included for comparison.
- the present invention relates to a method of administering a CNTF protein to treat diseases and disorders in humans or animals.
- CG chick ciliary ganglion
- electrophoretic mobility data indicated that all of the modified human CNTF molecules that migrated to the same position as rat CNTF had the single amino acid substitution Gln63Arg (Q63R), in which glutamine at position 63 is replaced with arginine.
- CNTF is characterized by its capacity to support the survival of dissociated ciliary neurons of E8 chick embryos.
- purified recombinant rat CNTF is as active as the native protein from rat, but four times more active than recombinant human CNTF (Masiakowski, et al., 1991, J. Neurosci. 5_Z:1003-1012 and in International Publication No. WO 91/04316, published on April 4, 1991).
- the same assay was utilized to determine the biological activity of the altered molecules prepared as described above.
- all modified CNTF molecules that had the Q63R substitution exhibited an increased ability to support the survival of ciliary ganglion neurons as compared to the parent human CNTF protein.
- an indication of the potential biological activity of each of the molecules may also be obtained by determining the effect of each modification on the ability of the molecules to bind to the CNTF receptor.
- a ciliary neurotrophic factor protein As used herein, the terms "a ciliary neurotrophic factor protein”, “a CNTF protein”, “a ciliary neurotrophic factor molecule” and “a CNTF molecule” refer to human ciliary neurotrophic factor and modified ciliary neurotrophic factors.
- modified ciliary neurotrophic factor refers to CNTF proteins and polypeptides that have certain amino acid substitutions and/or deletions in the arr ⁇ no acid residue sequence of human CNTF which result in modified CNTF proteins and polypeptides that exhibit binding to the CNTF receptor and, therefore, would be expected to have enhanced biological, immunogenic and/or purification properties.
- CNTF proteins of the present invention may also be “pegylated” by the addition of polyethylene glycol polymers in order to enhance stability and/or bioavailability.
- a particularly preferred "modified ciliary neurotrophic factor” according to the invention contains certain amino acid substitutions and deletions in the human CNTF protein and exhibits enhanced binding to the human CNTF receptor and therefore, would be expected to have enhanced biological properties, and specifically include AX- 13, AX-2 and AX-15, described in more detail infra.
- the CNTF molecules useful for practicing the present invention may be prepared by cloning and expression in a prokaryotic or eukaryotic expression system as described, for example in Masiakowski, et al., 1991, J. Neurosci. 57:1003-1012 and in International Publication No. WO 91/04316, published on April 4, 1991.
- the recombinant CNTF gene may be expressed and purified utilizing any number of methods.
- the gene encoding this protein may be subcloned into a bacterial expression vector, such as for example, but not by way of limitation, pCPHO.
- the recombinant CNTF proteins may be purified by any technique which allows for the subsequent formation of a stable, biologically active protein.
- they may be recovered from cells either as soluble proteins or as inclusion bodies, from which they may be extracted quantitatively by 8M guanidinium hydrochloride and dialysis. Further purification of the proteins, may be done by conventional ion exchange chromatography, hydrophobic interaction chromatography, reverse phase chromatography or gel filtration.
- CNTF proteins produced as described herein, or hybrids or mutants thereof may be used to promote differentiation, proliferation or survival in vitro or in vivo of cells that are responsive to CNTF, including cells that express receptors of the CNTF/IL-6/LIF receptor family, or any cells that express the appropriate signal transducing component, as described, for example, in Davis, et al., 1992, Cell 69:1121-1132. Mutants or hybrids may alternatively antagonize cell differentiation or survival.
- the present invention may be used to treat disorders of any cell responsive to CNTF or the CNTF /CNTF receptor complex.
- disorders of cells that express members of the CNTF/IL-6/LIF receptor family may be treated according to these methods. Examples of such disorders include, but are not limited to, obesity and diabetes.
- the present invention provides for methods in which a patient is treated with an effective amount of the modified CNTF protein, or a hybrid or mutant thereof.
- the modified CNTF proteins may be utilized to treat disorders or diseases as described for CNTF in International Publication No. WO91/04316 published on April 4, 1991 by Masiakowski, et al. and for the CNTF/CNTFR complex as described in International Publication No. WO91/19009 published on December 12, 1991 by Davis, et al. both of which are incorporated by reference in their entirety herein.
- Such diseases or disorders include degenerative diseases, such as retinal degenerations, diseases or disorders involving the spinal cord, cholinergic neurons, hippocampal neurons or diseases or disorders involving motor neurons, such as amyotrophic lateral sclerosis or those of the facial nerve, such as Bell's palsy.
- Other diseases or disorders that may be treated include obesity and diabetes
- rHCNTF human clinical trials using recombinant human CNTF (rHCNTF) have been carried out wherein subcutaneous administration of the protein was tested for its efficacy in slowing the progression of amyotrophic lateral sclerosis (ALS).
- ALS amyotrophic lateral sclerosis
- rHCNTF human clinical trials using recombinant human CNTF (rHCNTF) have been carried out wherein subcutaneous administration of the protein was tested for its efficacy in slowing the progression of amyotrophic lateral sclerosis (ALS).
- ALS amyotrophic lateral sclerosis
- rHCNTF ⁇ C13 also designated RPN160 or RG160
- RPN160 rHCNTF ⁇ C13
- rHCNTF ⁇ C13 retains full biological activity and is soluble at low temperatures (5-10°C) to at least 12 mg/ml. Yet, despite this far greater solubility, rHCNTF ⁇ C13 precipitates in a PBS solution upon incubation at 37°C for several hours, even at concentrations as low as 0.1 mg/ml. It was determined that the thermal instability of rHCNTF and rHCNTF ⁇ C13 was the result of aggregation that was initiated by intermolecular disulfide bond formation and depended strongly on protein concentration and temperature.
- modified CNTF proteins were obtained that exhibited far greater stability and maintained their biological activity after incubation for at least 7 days in PBS at 37°C.
- This property is maintained in rHCNTF, Q63R variants which have higher potency due to the substitution of the glutamine residue at position 63 by arginine.
- rHCNTF, C17A, Q63R, ⁇ C13 also designated RG297 shows greater biological potency than rHCNTF because of the Q63R substitution, greater solubility because of the ⁇ C13 deletion and greater stability because of the C17A substitution.
- AX-15 Another embodiment of a modified CNTF in the present invention is AX-2, which has a C17A substitution in the amino acid residue sequence of human CNTF and a truncation of the 15 C-terminal amino acid residues of human CNTF.
- AX-2, (rHCNTF, C17A ⁇ C15) differs from AX-15 solely in the absence of the Q63R substitution that is present in AX-15.
- the present invention contemplates a composition comprising a ciliary neurotrophic factor protein of the invention, such as the protein described herein as AX-15, and a carrier.
- Another object of the present invention is to provide a method of treating a disease or disorder comprising administering CNTF or a modified ciliary neurotrophic factor, such as the protein described herein as AX-15.
- the disease or disorder treated may be a degenerative disease and/or involve the spinal cord, motor neurons, cholinergic neurons or cells of the hippocampus.
- the method of treatment may be for treating a disease or disorder such as obesity or diabetes or treating a disease or disorder involving muscle atrophy.
- a further object of the present invention is to provide a method of inducing weight loss in a mammal comprising administration to the mammal of a ciliary neurotrophic factor protein, particularly AX-15.
- a specific embodiment of this invention involves inducing weight loss in a human.
- a CNTF protein such as AX-15
- the method of administering a CNTF protein, such as AX-15 may be used in the treatment of diet induced obesity or obesity of a genetically determined origin.
- a modified CNTF protein, such as AX-15 described herein may also be used in a method of preventing and/or treating the occurrence of gestational or adult onset diabetes in a human.
- any of the above-described methods involving the administration of CNTF or a modified CNTF, such as AX-15 described herein, may be practiced by administering the CNTF protein via a route of delivery selected from the group consisting of intravenous, intramuscular, intraocular, subcutaneous, intranasal, respiratory or intratracheal, such as by use of a nebulizer, and by intracolonic or vaginal suppositories.
- a CNTF protein, such as AX-15 described herein may be administered via the implantation of cells that release the modified ciliary neurotrophic factor.
- the present invention also provides for pharmaceutical compositions comprising CNTF or a modified CNTF protein or hybrid or mutant thereof, such as AX-15 described herein, as the sole therapeutic agent or in a complex with the CNTF receptor, in a suitable pharmacologic carrier for use in the treatment of obesity or gestational or adult onset diabetes.
- the active ingredient which may comprise CNTF or a modified CNTF should be formulated in a suitable pharmaceutical carrier for administration in vivo by any appropriate route including, but not limited to intranasal, intratracheal, by nebulizer, intraocular and oral.
- intranasal administration refers to delivery to the nose or nasal passageways by spray, drops, gel, inhalant or other means.
- intratracheal administration refers to delivery to the throat or tracheal lumen by spray, propellant, atomizer, injection or other means.
- nebulizer refers to the use of any device which reduces the formulation of the present invention to a fine spray for penetration into the lungs or nasal cavities.
- intraocular administration refers to delivery to the eye by drop, spray, ointment or other means.
- oral administration refers to delivery to the mouth, esophagus or stomach by pill, capsule, solution, tablet, lozenge, powder, spray or other means.
- the active ingredient may be formulated in a liquid carrier such as saline, incorporated into liposomes, microcapsules, polymer or wax-based and controlled release preparations.
- modified CNTF preparations are stable solutions, or formulated into tablet, pill or capsule forms.
- the concentration of the active ingredient used in the formulation will depend upon the effective dose required and the mode of administration used. The dose used should be sufficient to achieve circulating plasma concentrations of active ingredient that are efficacious. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems. Effective doses are expected to be within the range of from about .001 to about 1 mg/day. EXAMPLES
- Example 1 Electrophoretic Mobility of Modified Human CNTF Molecules Materials and Methods Preparation of Modified CNTF molecules Bacterial Strains and Plasmids E. coli K-12 RFJ26 is a strain that overproduces the lactose operon repressor.
- the expression vectors pRPN33, which carries the human CNTF gene and pRPNHO which carries the rat CNTF gene are nearly identical (Masiakowski, et al., 1991, J. Neurosci. 57_:1003-1012 and in International Publication No. WO 91 /04316, published on April 4, 1991.)
- Plasmid pRPN219 was constructed by first digesting pRPN33 with the restriction enzymes Nhel plus Hind3 and gel purifying the 4,081 bp fragment. The second, much smaller fragment which codes for part of the human CNTF gene was subsequently replaced with an 167 bp Nhel-Hind3 fragment that was obtained by PCR amplification from the rat gene using the primers RATTII-dniH: 5' ACGGTAAGCT TGGAGGTTCTC 3'; and RAT-Nhe-I-M: 5' TCTATCTGGC TAGCAAGGAA GATTCGTTCA GACCTGACTG CTCTTACG 3'.
- Plasmid pRPN228 was constructed in the same manner as pRPN219, except that the 167 bp replacement fragment was amplified using the DNA primers Rat-III-dniH-L- R : 5' AAG GTA CGA TAA GCT TGG AGG TTC TCT TGG AGT CGC TCT GCC TCA GTC AGC TCA CTC CAA CGA TCA GTG 3' and Rat-Nhe-I: 5' TCT ATC TGG CTA GCA AGG AAG 3'.
- Plasmids pRPN186, pRPN187, pRPN188, pRPN189, pRPN192, pRPN218, and . pRPN222 were generated by similar means or by direct exchange of DNA fragments using the unique restriction sites shown in Figure 1.
- the mobilities of human, rat and several chimeric CNTF molecules on reducing SDS- polyacrylamide gels are shown in Figure 2.
- the chimeric molecules RPN186, RPN189, RPN218 and RPN228 exhibit mobilities comparable to rat CNTF, whereas RPN187, RPN188, RPN192 and RPN222 exhibit mobilities comparable to human
- Figure 2 also provides a measure of the purity of the different recombinant proteins. By visual inspection, purity varies from 60% for RPN189 to better than 90% for RPN228.
- 125 TCNTF was stored at 4°C and used up to one week after preparation.
- 125 I-CNTF approximately 10,000 cpm was mixed with a 5 mg unlabelled CNTF and analyzed by native gel electrophoresis. One major band was visible by either Coomassie staining or autoradiography.
- 125 TCNTF also showed comparable activity to native CNTF in supporting survival of E8 chick ciliary neurons in culture.
- SCG Superior cervical ganglia
- NVF nerve growth factor
- penicillin 50 U/ml
- streptomycin 50 mg/ml
- Cultures were maintained at 37°C in a humidified 95% air/5% C0 2 atmosphere.
- Ganglion non-neuronal cells were eliminated by treatment with araC (10 mM) on days 1 and 3 of culture. Cultures were fed 3 times/week and were routinely used for binding assays within 2 weeks.
- MG87/CNTFR is a fibroblast cell line transfected with the human CNTF ⁇ receptor gene (Squinto, et al.,1990, Neuron 5:757-766; Davis et al., 1991, Science 253:59-63). Binding Assays
- Binding was performed directly on cell monolayers.
- Cells in culture wells were washed once with assay buffer consisting of phosphate buffered saline (PBS; pH 7.4), 0.1 mM bacitracin, 1 mM PMSF, 1 mg/ml leu ⁇ Jtin, and 1 mg/ml BSA.
- Assay buffer consisting of phosphate buffered saline (PBS; pH 7.4), 0.1 mM bacitracin, 1 mM PMSF, 1 mg/ml leu ⁇ Jtin, and 1 mg/ml BSA.
- PBS phosphate buffered saline
- bacitracin 1 mM PMSF
- 1 mg/ml leu ⁇ Jtin 1 mg/ml BSA
- BSA phosphate buffered saline
- Non-specific binding was determined in the presence of 1,000-fold excess of unlabelled CNTF.
- Specific binding towards MG87/CNTFR was
- the expression plasmid pRG632 is a high copy plasmid that encodes ampicillin resistance and the gene for human CNTF-C17A,Q63R ⁇ C13 (also referred to herein as either AX-1 or AX-13) with a unique Eag I restriction enzyme recognition sequence 3' to the stop codon.
- This plasmid was used to construct a human CNTF mutation C17A,Q63R, ⁇ C15 (designated AX-15) by PCR amplification of a 187 bp BseR I-Eagl DNA fragment that incorporates the ⁇ C15 mutation.
- the 5' primer ⁇ C15- 5' (5'-CCAGATAGAGGAGTTAATGATACTCCT-3') ⁇ encodes the BseR I site and the 3' primer , ⁇ C15-3' ⁇ (5'-
- GCGTCGGCCGCGGACCACGCTCATTACCCAGTCT GTGAGAAGAAATG-3' encodes the C-terminus of the AX-15 gene ending at Glyl85 followed by two stop codons and an Eag I restriction enzyme recognition sequence.
- This DNA fragment was digested with BseR I and Eag I and ligated into the same sites in pRG632.
- the resulting plasmid, pRG639 encodes the gene for AX- 15 (human CNTF C17A,Q63R, ⁇ C15).
- the ⁇ C15 mutation was then transferred as a 339 bp Hind III-Eag I DNA fragment into the corresponding sites within pRG421, a high copy number expression plasmid encoding the gene for kanamycin resistance and human CNTF C17A,Q63R, ⁇ C13.
- the resulting plasmid, pRG643, encodes the gene for AX-15 under transcriptional control of the lacUV5 promoter, and confers kanamycin resistance.
- the AX-15 gene DNA sequence was confirmed by sequence analysis.
- Pegylation of proteins has been shown to increase their in vivo potency by enhancing stability and bioavailability while minimizing immunogenicity. It is known that the properties of certain proteins can be modulated by attachment of polyethylene glycol (PEG) polymers, which increases the hydrodynamic volume of the protein and thereby slows its clearance by kidney filtration. (See, e.g. Clark, R., et al., " 1996, J. Biol. Chem._271: 21969-21977).
- PEG polyethylene glycol
- PEGylated AX-13 has better solubility and stability properties, at physiological pH, than unPEGylated AX-13. PEGylation has been shown to greatly enhance pharmacokinetic properties of AX-13 and would be expected to similarly enhance the properties of other CNTF proteins.
- AX-13 derived from E. coli was used for these studies.
- 20kD mPEG-SPA was obtained from Shearwater Polymers, Bicine from Sigma, and Tris-Glycine precast gels from Novex, CA.
- a small scale reaction study was set up to determine reaction conditions.
- 20kD mPEG SPA was reacted with purified AX-13 at a final concentration of 0.6 mg/ml, at 4°C in an amine-free buffer at a pH of 8.1. Molar ratios of PEG to protein were varied and two reaction times were used. The reaction was stopped by the addition of a primary amine in large excess. Reaction products were analyzed by reducing SDS-PAGE. The predominant modified species ran at a molecular weight of approximately 60 kD. Higher order modified bands that ran at higher molecular weights were also seen. Based on this study, an overnight reaction at a PEG-to-protein ratio of 4 was chosen.
- AX-13 at 0.6 mg/mL was reacted with 20 kD mPEG SPA in a Bicine buffer overnight at 4°C at a pH of 8.1.
- the reaction was stopped by the addition of a primary amine in large excess.
- the reaction product was diluted with a low salt buffer and applied to an ion-exchange column. The column was washed with a low salt buffer and eluted with a NaCl gradient.
- a good separation between higher order forms apparent MW >66kD on SDS-PAGE), a distinct pegylated species that ran at about 60kD and unpegylated AX-13 was obtained. Fractions corresponding to the 60kD band were tested in a bioassay.
- a very faint band of unpegylated AX-13 was noticed in the fractions corresponding to the 60kD band.
- the 60kD band was further purified by size exclusion chromatography (SEC) that resulted in baseline separation between unpegylated AX-13 and the 60kD band.
- SEC size exclusion chromatography
- E. coli strain RFJ141 containing pRG639 was grown in LB medium and expression of AX-15 protein was induced by the addition of lactose to 1% (w/v). Induced cells were harvested by centrifugation, resuspended in 20 mM Tris-HCl, pH 8.3, 5 mM EDTA, 1 mM DTT, and lysed by passage through a French pressure cell at 10,000 psi.
- the cell lysate was centrifuged and the pellet was resuspended in 8 M guanidinium- HC1, 50 mM Tris-HCl, pH 8.3, 0.05 mM EDTA then diluted with 5 volumes of 50 mM Tris-HCl, pH 8.3, 0.05 mM EDTA (Buffer A) followed by dialysis against Buffer A.
- the dialysate was loaded onto a Q-sepharose column equilibrated with Buffer A.
- the AX-15 protein was eluted by a linear gradient to 1 M NaCl in 10 column volumes of buffer.
- Fractions containing AX-15 were pooled and brought to 1 M (NH 4 ) 2 S0 4 by the slow addition of solid (NH 4 ) 2 S0 4 while maintaining the pH at 8.3 by the addition of NaOH.
- the pool was loaded onto a phenyl-sepharose column equilibrated with 1 M (NH 4 ) 2 S0 4 in Buffer A.
- the column was washed with 0.5 M (NH 4 ) 2 S0 4 in Buffer A, and the AX-15 protein was eluted by a linear gradient of decreasing(NH 4 ) 2 S0 4 concentration.
- Fractions containing AX-15 protein were pooled, dialyzed against 5 mM NaP0 4 , pH 8.3, then concentrated by ultrafiltration.
- the concentrated pool was fractionated on a Sephacryl S-100 column equilibrated with 5 mM NaP0 4 , pH 8.3.
- a recombinant, kanamycin resistant E. coli strain RFJ141 expressing the AX-15 protein under lac promoter control (pRG643) was grown to an intermediate density of 30-35 AU 550 (Absorbance @ 550 nM) in a minimal salts, glucose medium containing 20 ⁇ g/ml kanamycin.
- Expression of AX-15 protein was induced by addition of IPTG (isopropyl thiogalactoside) to 1.0 mM and the fermentation was continued for an additional 8 hr.
- AX-15 protein was expressed as insoluble inclusion bodies following IPTG induction.
- Inclusion bodies were released from the harvested cells by disruption via repeated passage of cooled (0-10°C) cell paste suspension through a continuous flow, high pressure (>8,000 psi) Niro Soavi homogenizer. The homogenate was subjected to two passages through a cooled (4-8°C) continuous flow, high speed (>17,000 x G) Sharpies centrifuge (source) to recover inclusion bodies.
- Recovered inclusion bodies were extracted in 8.0 M guanidine HC1 with 1.0 mM DTT.
- the AX-15 protein/ guanidine solution was diluted into 50 mM Tris-HCl, 1.0 mM DTT, 0.05 mM EDTA, pH 8.0-8.3, and diafiltered versus diluent buffer with AGT 5,000 mwco hollow fiber filters (ACG Technologies, Inc.).
- the resulting solution, containing refolded AX-15 was filtered through a Microgon 0.22 ⁇ m hollow fiber filter (ACG Technologies, Inc.) prior to chromatographic purification. 5
- the filtered AX-15 solution described above was loaded onto a 16.4 L DEAE Sepharose (Pharmacia) column at 10.9 mg/ml resin and washed with 50 L of 50 mM o Tris, pH 8.0-8.3, 1.0 mM DTT, and 0.05 mM EDTA buffer.
- the AX-15 protein was eluted from the column with a 120 mM NaCl step in the same Tris buffer. Eluate exceeding a previously established 280 nM absorbance criteria of 40% maximum A 280 on the ascending portion of the peak and 20% of maximum A 2g0 on the descending portion of the peak was pooled and either stored frozen (-30°C) or used in the next 5 step of the purification procedure.
- the AX-15 protein was eluted with a 125 mM ammonium sulfate, Tris buffer wash step. Eluate exceeding previously established 280 nM absorbance criteria of 100% maximum A 280 on the ascending portion of the peak and 20% of maximum A 2g0 on the descending portion of the peak was pooled. 5 Eluate was simultaneously diluted 1:4 into 50 mM Tris, pH 8.0 -8.3 buffer without salt to reduce its conductivity. Pooled material was stored frozen (-30°C) or used in the following step.
- HIC hydrophobic interaction chromatography
- the AX-15 protein was eluted with a 77.0 5 L step of 5.0 mM sodium phosphate, 130 mM NaCl, pH 7.0-7.2. The eluate was simultaneously diluted 1:5 into 10.0 mM sodium phosphate, pH 9.0-9.2 buffer without salt to reduce conductivity and increase pH. Peak material exceeding 20% maximum A 280 on the ascending portion of the peak and 20% of the maximum A 280 on the descending portion of the peak was pooled. Pooled AX-15 protein was stored frozen (-30°C) or used in the following step.
- the pooled AX- 15 protein was filtered through Millipak 0.22 ⁇ m filters and stored at -80°C prior to dispensing or formulation.
- the amino acid sequence of AX-15 produced follows. Alternatively, one could produce a sequence which contains a methionine residue before the initial alanine.
- mice Normal (8 weeks) C57BL/6J mice were obtained from Taconic. The mice received daily subcutaneous injections of vehicle or AX-15. The animals were weighed daily and food intake over 24-hours was determined between days 3 and 4.
- ob/ob mice produce a truncated, non-functional gene product (leptin). These mice are hyperphagic, hyperinsulinemic, and markedly obese.
- mice C57BL/6J ob/ob mice were obtained from Jackson Laboratory and used for experiments at 12-14 weeks of age. The mice received daily subcutaneous injection of vehicle, AX-15, or leptin. Pair-fed group was given the average amount (g) of food consumed by animals treated with AX-15 (0.3 mg/kg). Body weights were obtained daily and food intake over 24-hours was determined between days 3 and 4. On day 8, the animals were sacrificed and carcass analysis was performed.
- AKR/J mice have been shown to be very susceptible to diet induced obesity by increasing body fat content. Although the gene environment(diet) interaction is not completely known regarding this kind of dietary obesity, like in human obesity, the genotype is polygenic. AKR/J mice were obtained from Jackson Laboratory and put on a high fat diet (45% fat; Research Diets) at age 10-12 weeks old. All experiments commenced after 7 weeks on high fat diet. The mice received daily subcutaneous injection of vehicle, AX-15, or leptin. Pair-fed group was given the average amount (g) of food consumed by animals treated with AX-15 (0.1 mg/kg). The animals were weighed daily and food intake over 24-hours was determined between days 3 and 4. On day 8, the animals were sacrificed and sera were obtained for insulin and corticosterone measurements.
- Recombinant human AX-15 was manufactured as set forth above and leptin was purchased from R & D Systems.
- mice AX-15 reduced body weight in normal mice in a dose dependent manner. In 6 days, the animals lost approximately 4%, 11%, and 16% of their body weight at 0.1 mg/kg, 0.3 mg/kg, and 1 mg/kg, respectively ( Figure 3). ob/ob mice
- Leptin was also effective in decreasing body weight in ob/ob mice. At 1 mg/kg, leptin decreased body weight 6% in 7 days, following a course almost identical to that of AX-15 given at 0.1 mg/kg (Figure 4).
- AX-15 reduced body weight in DIO mice dose dependently. Within one week, the animals lost approximately 14%, 26%, and 33% of their body weight when given AX- 15 at 0.1 mg/kg, 0.3 mg/kg, and 1 mg/kg, respectively (Figure 5). Comparing the effects of the AX-15 treatment and the pair-fed control animals, there was a small but significant difference between the 2 groups, suggesting that decrease food intake was probably the primary, although not the only, cause of weight loss with AX-15 treatment. Indeed, AX-15 significantly attenuated the obesity associated hyperinsulinemia in DIO mice, whereas merely reducing food intake (pair-fed) did not (Figure 6A). In addition, AX : 15 did not cause elevation of corticosterone levels, which is a common effect of food restriction (Figure 6B).
- DIO mice are leptin resistant; no weight loss effect was observed in these animals with daily injection of leptin (1 mg/kg; Figure 5).
- AX-15 caused weight loss in normal mice in a dose dependent manner.
- AX-15 induced weight loss in ob/ob mice in a dose dependent manner.
- AX-15 (0.1 mg/kg) was as effective as leptin (1 mg/kg) in causing weight loss in ob/ob mice.
- AX-15 caused weight loss in diet-induced obesity mice in a dose dependent manner, whereas leptin was ineffective.
- AX-15 treatment attenuated obesity associated hyperinsulinemia in DIO mice; this effect was not observed in pair-fed control animals.
- AX-15 was more effective in inducing weight loss in DIO mice than normal or ob/ob mice.
- AX-15 in reducing body weight in leptin resistant mouse model suggests that AX-15 may also be effective in reducing body weight in obese humans who are resistant or unresponsive to leptin.
- a model of human obesity is the AKR/J mice which are susceptible to diet-induced obesity (DIO) by an increase in body fat content analogous to humans, and as in human obesity the genotype is polygenic.
- DIO diet-induced obesity
- AX-15 administered via the intranasal route can be absorbed within the airway and/or through the mucosal lining of the nasal and respiratory tract and achieve serum levels that are in the efficacious range, based upon comparison to levels achieved following subcutaneous injection.
- AX-15 delivered via an intranasal route was effective in reducing body weight and food intake in DIO mice. Therefore, intranasal delivery can effectively be utilized as a route of administration for AX-15 in treating appropriate disorders such as obesity and diabetes.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Lock And Its Accessories (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01937817A EP1365785A2 (en) | 2000-05-24 | 2001-05-22 | Use of ciliary neurotrophic factor |
CA002409956A CA2409956A1 (en) | 2000-05-24 | 2001-05-22 | Use of ciliary neurotrophic factor |
AU2001263514A AU2001263514A1 (en) | 2000-05-24 | 2001-05-22 | Use of ciliary neurotrophic factor |
JP2001585793A JP2003535831A (en) | 2000-05-24 | 2001-05-22 | Use of ciliary neurotrophic factor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/577,468 US6767894B1 (en) | 1998-02-27 | 2000-05-24 | Use of ciliary neurotrophic factor |
US09/577,468 | 2000-05-24 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001089550A2 true WO2001089550A2 (en) | 2001-11-29 |
WO2001089550A3 WO2001089550A3 (en) | 2003-07-10 |
Family
ID=24308868
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/040783 WO2001089550A2 (en) | 2000-05-24 | 2001-05-22 | Use of ciliary neurotrophic factor |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1365785A2 (en) |
JP (1) | JP2003535831A (en) |
AU (1) | AU2001263514A1 (en) |
CA (1) | CA2409956A1 (en) |
WO (1) | WO2001089550A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005053728A2 (en) * | 2003-12-01 | 2005-06-16 | Xantos Biomedicine Ag | Obesity-associated proteins and the use thereof in therapy and diagnosis |
WO2006017156A2 (en) * | 2004-07-09 | 2006-02-16 | Regeneron Pharmaceuticals, Inc. | Methods for identifying a candidate for treatment of obesity |
WO2006041922A2 (en) * | 2004-10-08 | 2006-04-20 | Dara Biosciences, Inc. | Agents and methods for administration to the central nervous system |
WO2016070419A1 (en) * | 2014-11-07 | 2016-05-12 | 陕西麦科奥特科技有限公司 | Ciliary neurotrophic factor nasal delivery system and preparation method and use thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991004316A2 (en) * | 1989-09-15 | 1991-04-04 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Ciliary neurotrophic factor |
WO1991019009A1 (en) * | 1990-06-01 | 1991-12-12 | Regeneron Pharmaceuticals, Inc. | The ciliary neurotrophic factor receptor |
WO1998022128A1 (en) * | 1996-11-19 | 1998-05-28 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Use of cntf (ciliary neurotrophic factor) receptor activators for the treatment of obesity |
EP1010432A1 (en) * | 1997-01-23 | 2000-06-21 | Sumitomo Pharmaceuticals Company, Limited | Remedies for diabetes |
-
2001
- 2001-05-22 JP JP2001585793A patent/JP2003535831A/en not_active Withdrawn
- 2001-05-22 WO PCT/US2001/040783 patent/WO2001089550A2/en not_active Application Discontinuation
- 2001-05-22 CA CA002409956A patent/CA2409956A1/en not_active Abandoned
- 2001-05-22 EP EP01937817A patent/EP1365785A2/en not_active Withdrawn
- 2001-05-22 AU AU2001263514A patent/AU2001263514A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1991004316A2 (en) * | 1989-09-15 | 1991-04-04 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Ciliary neurotrophic factor |
WO1991019009A1 (en) * | 1990-06-01 | 1991-12-12 | Regeneron Pharmaceuticals, Inc. | The ciliary neurotrophic factor receptor |
WO1998022128A1 (en) * | 1996-11-19 | 1998-05-28 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Use of cntf (ciliary neurotrophic factor) receptor activators for the treatment of obesity |
EP1010432A1 (en) * | 1997-01-23 | 2000-06-21 | Sumitomo Pharmaceuticals Company, Limited | Remedies for diabetes |
Non-Patent Citations (3)
Title |
---|
GLOAGUEN I ET AL: "Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1997 JUN 10) 94 (12) 6456-61., XP002216008 cited in the application * |
MILLER, R. G. (1) ET AL: "Toxicity and tolerability of recombinant human ciliary neurotrophic factor in patients with amyotrophic lateral sclerosis." NEUROLOGY, (1996) VOL. 47, NO. 5, PP. 1329-1331., XP001064801 * |
MILLER, ROBERT G. (1) ET AL: "A placebo-controlled trial of recombinant human ciliary neurotrophic (rhCNTF) factor in amyotrophic lateral sclerosis." ANNALS OF NEUROLOGY, (1996) VOL. 39, NO. 2, PP. 256-260., XP008005507 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005053728A2 (en) * | 2003-12-01 | 2005-06-16 | Xantos Biomedicine Ag | Obesity-associated proteins and the use thereof in therapy and diagnosis |
WO2005053728A3 (en) * | 2003-12-01 | 2005-10-27 | Xantos Biomedicine Ag | Obesity-associated proteins and the use thereof in therapy and diagnosis |
WO2006017156A2 (en) * | 2004-07-09 | 2006-02-16 | Regeneron Pharmaceuticals, Inc. | Methods for identifying a candidate for treatment of obesity |
WO2006017156A3 (en) * | 2004-07-09 | 2006-08-03 | Regeneron Pharma | Methods for identifying a candidate for treatment of obesity |
US7279282B2 (en) | 2004-07-09 | 2007-10-09 | Scott Mellis | Methods for identifying a candidate for treatment of obesity |
WO2006041922A2 (en) * | 2004-10-08 | 2006-04-20 | Dara Biosciences, Inc. | Agents and methods for administration to the central nervous system |
WO2006041922A3 (en) * | 2004-10-08 | 2006-07-27 | Dara Biosciences Inc | Agents and methods for administration to the central nervous system |
WO2016070419A1 (en) * | 2014-11-07 | 2016-05-12 | 陕西麦科奥特科技有限公司 | Ciliary neurotrophic factor nasal delivery system and preparation method and use thereof |
Also Published As
Publication number | Publication date |
---|---|
JP2003535831A (en) | 2003-12-02 |
EP1365785A2 (en) | 2003-12-03 |
AU2001263514A1 (en) | 2001-12-03 |
CA2409956A1 (en) | 2001-11-29 |
WO2001089550A3 (en) | 2003-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6767894B1 (en) | Use of ciliary neurotrophic factor | |
JP2702811B2 (en) | Modified ciliary neurotrophic factor | |
EP0785948B1 (en) | Analogs of keratinocyte growth factor | |
WO1994012219A2 (en) | Modified insulin-like growth factors | |
AU2008324426B2 (en) | Novel neurturin conjugates for pharmaceutical use | |
WO1996033216A1 (en) | Truncated igf-i | |
WO2001089550A2 (en) | Use of ciliary neurotrophic factor | |
WO2001064742A1 (en) | Modified bdnf | |
EP0849276A1 (en) | Anti-obesity proteins | |
EA017377B1 (en) | Erythropoietin fusion protein | |
WO2001012810A1 (en) | Modified ciliary neurotrophic factor, method of making and methods of use thereof | |
AU5068502A (en) | Analogs of keratinocyte growth factor | |
AU2813399A (en) | Analogs of keratinocyte growth factor, nucleic acids encoding such analogs, processes of making and methods of using | |
MXPA97010239A (en) | Anti-obesi proteins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2409956 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001263514 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001937817 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001937817 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001937817 Country of ref document: EP |